Insights from 2024 EHA Annual Meeting

 

Videos
13:38

Insights from 2024 EHA Annual Meeting

Top 5 Impactful MPN Abstracts From Summer Conferences

FEATURING Prithviraj Bose
  • 1 view
  • July 31, 2024
06:45

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Relationship Between Hemoglobin and QoL in Transfusion-Dependent Patients With LR-MDS Receiving Luspatercept or Epoetin Alfa

FEATURING Esther Oliva
  • 18 views
  • July 26, 2024
02:01

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagraxofusp

FEATURING Emanuele Angelucci
  • 4 views
  • July 23, 2024
14:27

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Limited Stage HL - Current SOC, Future Directions, and Incorporating BV and Nivo

FEATURING Steven Park
  • 28 views
  • July 18, 2024
  • 1
07:33

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Sonrotoclax and Zanubrutinib Combination Therapy for R/R MCL

FEATURING Constantine Tam
  • 8 views
  • July 18, 2024
13:17

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Golcadomide, an Oral CELMoD, + R-CHOP in Patients With Untreated Aggressive B-Cell Lymphoma

FEATURING Marc Hoffmann
  • 14 views
  • July 18, 2024
27:49

Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

FEATURING Talha Badar
  • 325 views
  • July 16, 2024
  • 4
14:47

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's Lymphoma With AVD+BV+Nivo

FEATURING Maher Salamoon
  • 108 views
  • July 9, 2024
  • 4
13:58

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctuary CNS Involvement in B-Cell Malignancies

FEATURING Maher Salamoon
  • 80 views
  • July 9, 2024
  • 2
06:03

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Zanubrutinib vs. Acalabrutinib in B-cell Malignancies - An AE-Based Economic Analysis

FEATURING Talha Munir
  • 43 views
  • July 8, 2024
09:15

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Low-Molecular-Weight Heparin and VTE in Newly Diagnosed ALL - Results From HOVON-100

FEATURING Mandy Lauw
  • 58 views
  • July 8, 2024
06:55

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Results by Cytogenetic Risk From PERSEUS - Dara-VRd in Transplant-Eligible Newly Diagnosed MM

FEATURING Meletios Dimopoulos
  • 3 views
  • July 5, 2024
06:31

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Impact of Anemia on Clinical Outcomes in MF Patients Treated With Ruxolitinib - Result of the JUMP Study

FEATURING Haifa Kathrin Al-Ali
  • 32 views
  • July 3, 2024
08:01

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL

FEATURING Stephen S. Opat
  • 25 views
  • July 3, 2024
14:32

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Infectious Complications in BCMA- and GPRC5D-Targeted Immunotherapy for MM

FEATURING Julia Mersi
  • 11 views
  • July 2, 2024
03:52

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Factor AML

FEATURING Gautam Borthakur
  • 123 views
  • July 1, 2024
  • 2
04:03

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: PROs After Epcoritamab in R/R Follicular Lymphoma

FEATURING Wojciech Jurczak
  • 15 views
  • July 1, 2024
05:27

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Updated Trends in Real-World Outpatient Administration of CAR-T in R/R NHL

FEATURING Radhika Bansal
  • 15 views
  • June 30, 2024
06:39

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Axicabtagene Ciloleucel in R/R Primary Mediastinal B-Cell Lymphoma

FEATURING Jean Galtier
  • 11 views
  • June 30, 2024
12:32

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Sequential Administration of Bispecific Antibodies and Anti-BCMA CAR-T in R/R MM

FEATURING David Fandrei
  • 75 views
  • June 30, 2024
06:51

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: SYMPATICO Study - Ibrutinib + Venetoclax in MCL With TP53 Mutations

FEATURING Wojciech Jurczak
  • 12 views
  • June 30, 2024
10:03

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: SEQUOIA Trial Arm D - Zanubrutinib + Venetoclax for Treatment-Naïve CLL/SLL With Del(17p) and/or TP53

FEATURING Paolo Ghia
  • 45 views
  • June 28, 2024
  • 1
12:04

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: The Impact of TP53 Mutation Burden on Risk & Treatment Decision in Newly Diagnosed CLL

FEATURING Maher Salamoon
  • 146 views
  • June 28, 2024
  • 3
06:54

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory WM/LPL

FEATURING Mazyar Shadman
  • 26 views
  • June 28, 2024
05:41

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in High-Risk CLL

FEATURING Catherine Coombs
  • 51 views
  • June 28, 2024
  • 1
06:30

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: QuANTUM-First Trial - Newly Diagnosed FLT3-ITD+ AML Patients Receiving Chemo + Quizartinib vs. Placebo

FEATURING Esther Oliva
  • 54 views
  • June 28, 2024
11:23

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated IDH1 AML

FEATURING Jorge Cortés
  • 11 views
  • June 28, 2024
14:39

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: REVIVE Study - Updated Long-Term Results of Hepcidin Mimetic Rusfertide in PV

FEATURING Kristen Pettit
  • June 28, 2024
04:33

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Daratumumab for iTTP

FEATURING Júlia Weisinger
  • 109 views
  • June 28, 2024
36:10

Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

FEATURING Samer Al Hadidi
  • 324 views
  • June 27, 2024
  • 4
09:52

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors

FEATURING Joshua Zeidner
  • 27 views
  • June 26, 2024
11:40

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R AML

FEATURING Wei-Ying Jen
  • 171 views
  • June 26, 2024
10:27

Insights from 2024 EHA Annual Meeting

Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib in Newly Diagnosed Ph+ ALL

FEATURING Jose-Maria Ribera
  • 68 views
  • June 24, 2024
19:14

2024 ASCO® Annual Meeting Insights Hub

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and EHA

FEATURING Kerry Rogers, Jennifer Woyach
  • 228 views
  • June 21, 2024
  • 1
07:38

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: TRANSCEND NHL 001 Study - Liso-Cel in R/R MCL - Analyzing Therapy Lines and BTKi Response

FEATURING Manali Kamdar
  • 43 views
  • June 20, 2024
12:24

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transplant-Eligible NDMM

FEATURING Pieter Sonneveld
  • 42 views
  • June 20, 2024
12:00

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: QUAZAR AML-001 - Oral Azacitidine Maintenance in AML Pts With Myelodysplasia-Related Changes

FEATURING Maria Teresa Voso
  • 65 views
  • June 20, 2024